Cancer cell resistance is mediated, in part, by treatment-induced loss of ERK-dependent negative feedback and the resulting upstream reactivation of RAF-MEK-ERK signaling (Klomp et al., 2021; Lake et al., 2016). Here, MAP2K7 is linked to cancer.